APRECAP works by blocking neurokinin-1 (NK1) receptors in the central nervous system, inhibiting the signals that trigger vomiting.
Recommended for:
Adults undergoing chemotherapy
As part of combination therapy with serotonin receptor antagonists and corticosteroids
Prevention of both acute and delayed nausea and vomiting
Under supervision of an oncologist
Prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy in adults
Take orally: 125mg capsule one hour before chemotherapy on day 1, followed by one 80mg capsule daily on days 2 and 3. Use as part of a combination antiemetic regimen.
Contraindications:
Hypersensitivity to aprepitant or any excipients
Co-administration with drugs that are CYP3A4 substrates with a narrow therapeutic index
Severe hepatic impairment
Pregnancy and breastfeeding without medical consultation
Side Effects:
Fatigue
Dyspepsia, gastritis
Dizziness
Constipation, diarrhoea
Elevated liver enzymes
Allergic skin reactions